Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
report (date of earliest event reported): September 20, 2006
ZIOPHARM
Oncology, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
0-32353
|
84-1475642
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
1180
Avenue of the Americas, 19th
Floor
New
York, NY 10036
(Address
of principal executive offices) (Zip Code)
(646)
214-0700
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
8.01. Other Events.
On
September 20, 2006, the Company issued a press release announcing that it had
received approval for its application to list its common shares on The NASDAQ
Capital Market. The Company’s common shares will begin trading on The NASDAQ
Capital Market on Friday, September 22, 2006 under the symbol “ZIOP.” The
trading of ZIOPHARM’s shares on the Over-the-Counter Bulletin Board will cease
at the close of business on Thursday, September 21, 2006.
Item
9.01 Financial Statements and Exhibits.
|
99.1 |
Press
Release dated September 20, 2006.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
Date:
September 20, 2006 |
ZIOPHARM
Oncology, Inc.:
|
|
|
|
|
By: |
/s/ Richard
E. Bagley |
|
RICHARD
E. BAGLEY, President, |
|
Chief
Operating Officer and Chief Financial
Officer |
Exhibit
Index
Exhibit
No.
|
Description
|
|
|
99.1
|
Press
Release date September 20, 2006
|